May 13 (Reuters) - Merck said on Monday it had discontinued the arm of a late-stage study, which tested an experimental antibody-based drug with its blockbuster immunotherapy Keytruda for some patients with the most severe form of skin cancer. (Reporting by Mariam Sunny in Bengaluru; Editing by Tasim Zahid)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
131.5 USD | +0.63% | +2.39% | +20.61% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+20.61% | 333B | |
+48.39% | 779B | |
-6.13% | 354B | |
+10.00% | 301B | |
+19.45% | 249B | |
-1.60% | 216B | |
+11.74% | 214B | |
+5.80% | 163B | |
-2.50% | 159B | |
+1.94% | 121B |
- Stock Market
- Equities
- MRK Stock
- News Merck & Co., Inc.
- Merck stops skin cancer combination therapy testing in late-stage study